Catalyst Watch – Vol. 2, Edition 10 (4/4/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List – Update: CYTK: […]

March 21 Biotech Update

[This was written Friday but the site was down and I was unable to post it. I am publishing it as it was Friday and will write another column later today for more recent news] Well, it was a manic day with a very nice win followed by the broader morning bloodbath in the sector. […]

February 7 Biotech Update- Recovery Edition

Despite the disappointing jobs report, the market held up fairly well and the biotech sector doing well (and seems to be getting relatively stronger as the day goes on). Large caps appeared to be a little stronger than the broader market, although perhaps that would have been more pronounce if it were not for GILD […]

February 6 Biotech Update- A Mixed Day

It is good day in the market but a bad day for large cap biotechs as most underperformed (large cap pharma was a little different but still not great). Small and mid caps seemed to do better but I would not say that they clearly outperformed the market (but still did better than the large […]

February 3 Biotech Update- The Bloodbath Edition

It was another rough day in the market with a familiar pattern- market weak, large cap biotechs outperforming the broader market and small cap biotechs underperforming. It makes sense in that risk off means selling biotechs but large cap biotechs have a valuation buffer in their growing free cash flow. This is not to say […]